Proteolytic Cleavage of Bioactive Peptides and Protease-Activated Receptors in Acute and Post-Colitis
暂无分享,去创建一个
P. Hulpiau | H. Koistinen | U. Stenman | A. Lambeir | I. De Meester | M. Berg | B. D. De Winter | H. Ceuleers | J. D. De Man | Nikita Hanning | M. De Bruyn | Cedric Hermans | Paco Hulpiau
[1] A. Lambeir,et al. The Effect of a Novel Serine Protease Inhibitor on Inflammation and Intestinal Permeability in a Murine Colitis Transfer Model , 2021, Frontiers in Pharmacology.
[2] I. De Meester,et al. Local Colonic Administration of a Serine Protease Inhibitor Improves Post-Inflammatory Visceral Hypersensitivity in Rats , 2021, Pharmaceutics.
[3] D. McKay,et al. Epithelial production of elastase is increased in inflammatory bowel disease and causes mucosal inflammation , 2021, Mucosal Immunology.
[4] J. Wallace,et al. Increased Mucosal Thrombin is Associated with Crohn’s Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation , 2020, Journal of Crohn's & colitis.
[5] A. Gargouri,et al. Fecal Serine Protease Profiling in Inflammatory Bowel Diseases , 2020, Frontiers in Cellular and Infection Microbiology.
[6] F. Barreau,et al. Protease-Activated Receptors in the Intestine: Focus on Inflammation and Cancer , 2019, Front. Endocrinol..
[7] W. Shih,et al. µ‐opioid receptor, β‐endorphin, and cannabinoid receptor‐2 are increased in the colonic mucosa of irritable bowel syndrome patients , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[8] G. Farrugia,et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS , 2019, Gut.
[9] J. Fichna,et al. The place of tachykinin NK2 receptor antagonists in the treatment diarrhea-predominant irritable bowel syndrome. , 2019, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[10] J. Fichna,et al. Enkephalinase inhibitors, potential therapeutics for the future treatment of diarrhea predominant functional gastrointestinal disorders , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[11] F. Russo,et al. Adipose Tissue-Derived Biomarkers of Intestinal Barrier Functions for the Characterization of Diarrhoea-Predominant IBS , 2018, Disease markers.
[12] Å. Keita,et al. Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis , 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[13] O. Schilling,et al. Specificity profiling of human trypsin-isoenzymes , 2018, Biological chemistry.
[14] A. Lambeir,et al. Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome , 2018, British journal of pharmacology.
[15] G. Barbara,et al. Protease-activated receptor 1 is implicated in irritable bowel syndrome mediators–induced signaling to thoracic human sensory neurons , 2018, Pain.
[16] J. Fichna,et al. Antinociceptive potency of enkephalins and enkephalinase inhibitors in the mouse model of colorectal distension—proof‐of‐concept , 2018, Chemical biology & drug design.
[17] M. Hollenberg,et al. Functional Proteomic Profiling of Secreted Serine Proteases in Health and Inflammatory Bowel Disease , 2018, Scientific Reports.
[18] L. Hellman,et al. Extended cleavage specificity of human neutrophil cathepsin G: A low activity protease with dual chymase and tryptase-type specificities , 2018, PloS one.
[19] B. Kuster,et al. Protease signaling through protease activated receptor 1 mediate nerve activation by mucosal supernatants from irritable bowel syndrome but not from ulcerative colitis patients , 2018, PloS one.
[20] E. Mayer,et al. Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome. , 2017, Gastroenterology.
[21] M. Jiang,et al. Unconjugated bilirubin ameliorates the inflammation and digestive protease increase in TNBS-induced colitis , 2017, Molecular medicine reports.
[22] P. Sutton,et al. Protease-activated Receptor 1 Plays a Proinflammatory Role in Colitis by Promoting Th17-related Immunity , 2017, Inflammatory bowel diseases.
[23] Y. Taché,et al. Epithelial expression and function of trypsin-3 in irritable bowel syndrome , 2017, Gut.
[24] A. Lambeir,et al. Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases , 2016, World journal of gastroenterology.
[25] J. Timmermans,et al. P2X3 Receptors Mediate Visceral Hypersensitivity during Acute Chemically-Induced Colitis and in the Post-Inflammatory Phase via Different Mechanisms of Sensitization , 2015, PloS one.
[26] W. Henderson,et al. Altered vasoactive intestinal peptides expression in irritable bowel syndrome patients and rats with trinitrobenzene sulfonic acid-induced colitis. , 2015, World journal of gastroenterology.
[27] N. Bunnett,et al. Corrigendum: Biased Signaling of Protease-Activated Receptors , 2015, Front. Endocrinol..
[28] N. Bunnett,et al. Biased Signaling of Protease-Activated Receptors , 2014, Front. Endocrinol..
[29] N. Ruyssers,et al. Histamine H4 and H1 receptors contribute to postinflammatory visceral hypersensitivity , 2014, Gut.
[30] N. Cenac. Protease-activated receptors as therapeutic targets in visceral pain. , 2013, Current neuropharmacology.
[31] S. Hua,et al. Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions , 2013, Front. Pharmacol..
[32] John E. Murphy,et al. Global Substrate Profiling of Proteases in Human Neutrophil Extracellular Traps Reveals Consensus Motif Predominantly Contributed by Elastase , 2013, PloS one.
[33] K. Garsed,et al. Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea: origin and effect of gut transit , 2013, Gut.
[34] H. Lee,et al. Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea , 2013, Scandinavian journal of gastroenterology.
[35] Alma L Burlingame,et al. Global identification of peptidase specificity by multiplex substrate profiling , 2012, Nature Methods.
[36] P. N. Shaw,et al. Study of beta endorphin metabolism in inflamed tissue, serum and trypsin solution by liquid chromatography–tandem mass spectrometric analysis , 2012, Analytical and Bioanalytical Chemistry.
[37] L. Fricker,et al. Substrate Specificity of Human Carboxypeptidase A6* , 2010, The Journal of Biological Chemistry.
[38] F. Avilés,et al. Characterization of the Substrate Specificity of Human Carboxypeptidase A4 and Implications for a Role in Extracellular Peptide Processing* , 2010, The Journal of Biological Chemistry.
[39] L. Blackshaw,et al. TRP channels: new targets for visceral pain , 2009, Gut.
[40] R. Langer,et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. , 2009, Gastroenterology.
[41] T. Wittmann,et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice , 2009, PAIN®.
[42] T. Wittmann,et al. Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. , 2009, The American journal of pathology.
[43] J. Sung,et al. Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients , 2009, Journal of Gastroenterology.
[44] H. Koistinen,et al. Nexin-1 inhibits the activity of human brain trypsin , 2009, Neuroscience.
[45] N. Vergnolle. Proteinase-activated receptors (PARs) in infection and inflammation in the gut. , 2008, The international journal of biochemistry & cell biology.
[46] Martin Strohalm,et al. mMass data miner: an open source alternative for mass spectrometric data analysis. , 2008, Rapid communications in mass spectrometry : RCM.
[47] S. Muhtaroğlu,et al. Ameliorative effects of bombesin and neurotensin on trinitrobenzene sulphonic acid-induced colitis, oxidative damage and apoptosis in rats. , 2008, World journal of gastroenterology.
[48] T. Wittmann,et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity , 2008, Gut.
[49] M. Hollenberg,et al. Trypsin IV or Mesotrypsin and p23 Cleave Protease-activated Receptors 1 and 2 to Induce Inflammation and Hyperalgesia* , 2007, Journal of Biological Chemistry.
[50] F. Nagy,et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[51] M. Steinhoff,et al. Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.
[52] S. Collins,et al. Visceral pain perception is determined by the duration of colitis and associated neuropeptide expression in the mouse , 2006, Gut.
[53] G. Rogler,et al. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo , 2006, Clinical and experimental immunology.
[54] N. Vergnolle,et al. CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.
[55] P. Brun,et al. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. , 2005, American journal of physiology. Gastrointestinal and liver physiology.
[56] G. Rogler,et al. Cathepsin D is up‐regulated in inflammatory bowel disease macrophages , 2004, Clinical and experimental immunology.
[57] G. Sanger. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain , 2004, British journal of pharmacology.
[58] D. Santini,et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. , 2004, Gastroenterology.
[59] J. Schwartz,et al. Cell-specific activity of neprilysin 2 isoforms and enzymic specificity compared with neprilysin. , 2002, The Biochemical journal.
[60] A. van Dorsselaer,et al. Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. , 2000, Biochemistry.
[61] C. Craik,et al. Cathepsin G Activates Protease-activated Receptor-4 in Human Platelets* , 2000, The Journal of Biological Chemistry.
[62] W. Falk,et al. Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin , 1999, Gut.
[63] R. Carraway,et al. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. , 1999, The Journal of clinical investigation.
[64] J. Otlewski,et al. Specificity of human cathepsin G. , 1998, Biochimica et biophysica acta.
[65] L. Hersh,et al. Identification of γ-Endorphin-Generating Enzyme as Insulin-Degrading Enzyme† , 1996 .
[66] J. Bai,et al. The Presence of Insulin‐degrading Enzyme in Human Ileal and Colonic Mucosal Cells , 1996, The Journal of pharmacy and pharmacology.
[67] H. Nagura,et al. Abnormal neuropeptide concentration in rectal mucosa of patients with inflammatory bowel disease , 1996, Journal of Gastroenterology.
[68] T. Kageyama,et al. Processing of the Precursors to Neurotensin and Other Bioactive Peptides by Cathepsin E (*) , 1995, The Journal of Biological Chemistry.
[69] H. Nagura,et al. Changes in neuropeptide‐containing nerves in human colonic mucosa with inflammatory bowel disease , 1994, Pathology international.
[70] C. Surrenti,et al. Colonic vasoactive intestinal polypeptide in ulcerative colitis , 1993, Journal of Physiology-Paris.
[71] H. Singh,et al. Dipeptidyl peptidase I from goat brain: Purification, characterization and its action on leu-enkephalin , 1993, Neurochemistry International.
[72] C. Maison,et al. Proteolysis of C3 on U937 cell plasma membranes. Purification of cathepsin G. , 1991, Journal of immunology.
[73] T. Tanaka,et al. Human leukocyte cathepsin G. Subsite mapping with 4-nitroanilides, chemical modification, and effect of possible cofactors. , 1985, Biochemistry.
[74] H. Kern,et al. Hormonal stimulation in the exocrine pancreas results in coordinate and anticoordinate regulation of protein synthesis , 1984, The Journal of cell biology.
[75] C. O'Morain,et al. Vasoactive intestinal peptide concentrations and immunocytochemical studies in rectal biopsies from patients with inflammatory bowel disease. , 1984, Gut.
[76] S. Hamilton,et al. Abnormalities of vasoactive intestinal polypeptide-containing nerves in Crohn's disease , 1980 .
[77] J. Powers,et al. Specificity of porcine pancreatic elastase, human leukocyte elastase and cathepsin G. Inhibition with peptide chloromethyl ketones. , 1977, Biochimica et biophysica acta.
[78] J. Sallenave,et al. Overexpression of Elastin Affects the Protease to Anti-Protease Balance and Protects Mice from Colitis , 2019 .
[79] B. Korkmaz,et al. Elastase-2/Leukocyte Elastase , 2013 .
[80] H. Koistinen,et al. Article in press-uncorrected proof Identification of novel peptide inhibitors for human trypsins , 2010 .
[81] N. Talley. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity , 2009 .
[82] D. Schomburg,et al. Pancreatic elastase II , 1998 .
[83] A. Blackburn. Neurotensin. , 1978, Journal of clinical pathology. Supplement.